An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma

Hoffmann-La Roche113 enrolled

Overview

This multicenter, observational study will evaluate the correlation between clinical and biological factors and International Prognostic Index (IPI) as prognostic factors in patients with diffuse large B-cell lymphoma receiving first-line treatment with MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy. Eligible patients receiving treatment according to standard of care and local guidelines will be followed for the duration of treatment (approximately 8 months) and during 1 year of follow-up.

Study Type

OBSERVATIONAL

Enrollment

113

Conditions

Diffuse Large B-Cell Lymphoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>18 years of age * Patients with diagnosed diffuse large B-cell lymphoma in first-line treatment with R-CHOP Exclusion Criteria: * Prior chemotherapy treatment for diffuse large B-cell lymphoma * Contra-indications or exclusion criteria according to the Summary of Product Characteristics for MabThera/Rituxan

Locations (1)

Unnamed facility

Bucharest, Romania

Outcomes

Primary Outcomes

Treatment patterns in clinical practice: Number of treatment cycles received

Time frame: approximately 4 years

Secondary Outcomes

Event-free survival

Time frame: approximately 4 years

Response rates

Time frame: approximately 4 years

Safety: Incidence of adverse events

Time frame: approximately 4 years